Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016

Brustugun, Odd Terje; Grønberg, Bjørn Henning; Fjellbirkeland, Lars; Helbekkmo, Nina; Aanerud, Marianne; Grimsrud, Tom Kristian; Helland, Åslaug; Møller, Bjørn; Nilssen, Yngvar; Strand, Trond Eirik; Solberg, Steinar

doi:10.1016/j.lungcan.2018.06.003

Cited by 34 publications

(36 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The probability of receiving surgical treatment in localized LC increased markedly, in contrast with findings from Norway where the percentage operated decreased for three major histologic types [10]. Our findings suggest that the rate of surgical treatment tends to be higher in Estonia than in several other countries.…”

Section: Discussioncontrasting

confidence: 71%

“…Nonetheless, squamous cell carcinoma remained the largest group within NSCLC, contrary to the findings in England and the US [22]. The changes in the proportion of adenocarcinoma in women in Estonia were similar to those observed in Norway [10], but the proportion in men remained considerably lower.…”

Section: Discussionmentioning

confidence: 44%

“…Better diagnostic accuracy was also reflected in increasing proportion of microscopic verification (77% from 2010 to 2016), although this indicator remained lower than in Europe (87%) and North-America (95%) from 2000 to 2014 [5]. Among cases with known stage, we observed a higher percentage of patients with distant metastases than that found in Norway [10]. The proportion of localized cases increased only for adenocarcinoma.…”

Section: Discussionmentioning

confidence: 56%

“…LC survival is higher in women than in men [6][7][8], and for non-small cell lung cancer (NSCLC) than for small cell lung cancer (SCLC) [6,9]. Survival declines with advancing age [6] and is strongly dependent on stage at diagnosis [9,10]. Screening high-risk individuals to achieve earlier diagnosis is currently being considered in numerous settings [11].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Patterns of survival and surgical treatment in lung cancer patients in Estonia by histologic type and stage, 1996–2016

et al. 2019

View full text Add to dashboard Cite

Background: Lung cancer (LC) remains the most frequent cause of cancer death worldwide. We aimed to examine long-term trends in LC survival in Estonia by age, gender, histologic type and stage, with specific focus on surgical treatment. Material and methods: Data on all incident cases of LC diagnosed from 1996 to 2016 were obtained from the Estonian Cancer Registry. Logistic regression was used to examine receipt of surgical treatment in localized LC. Relative survival ratios (RSR) were calculated, and excess hazard ratios (EHR) of death were estimated by stage with gender, age, histology and period of diagnosis as independent variables. Results: Among the total of 16,423 cases, squamous cell carcinoma remained the most common histologic type. The odds of receiving surgical treatment in localized LC increased significantly over time and were associated with age, gender and histologic type. Overall, the age-standardized 5-year RSR improved significantly from 10% in 1996-2002 to 16% in 2010-2016 (from 8% to 15% in men and from 15% to 20% in women). Larger survival gain was seen in younger patients, for non-small cell LC subtypes, and for surgically treated patients. For localized disease, the 5-year RSR increased by more than 20 percentage units, reaching 50% in men and 69% in women. For all stages, the adjusted EHR of death was significantly associated with age, histologic type and period of diagnosis. Conclusions: We observed a substantial improvement of relative survival, with considerable variations across patient groups. After adjustment for age, gender and histology, a significant survival increase over time was seen for all stages. The considerable survival gain observed for localized LC can largely be attributed to rapidly growing proportion of surgically treated patients. Further investigation of LC management practices, particularly the use of non-surgical treatment options is warranted.

show abstract

Section: Discussioncontrasting

confidence: 71%

Section: Discussionmentioning

confidence: 44%

Section: Discussionmentioning

confidence: 56%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Patterns of survival and surgical treatment in lung cancer patients in Estonia by histologic type and stage, 1996–2016

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Dessuten har Beslutningsforum for nye metoder hatt ett eller flere lungekreftmedikamenter på dagsordenen i 13 av 24 møter (54 %) i samme periode (3). Som det framgår under, har de nye behandlingsmulighetene bidratt til betydelig bedret overlevelse for pasientgruppen, og dermed en kraftig økende prevalens (4,5). Kombinasjonen av økt kompleksitet og økt pasientvolum har resultert i at arbeidet med lungekreftpasienter i spesialisthelsetjenesten er blitt atskillig mer omfattende enn for bare få år siden.…”

unclassified

Lungekreft: Forbedret prognose gir kapasitetsutfordringer

Brustugun¹,

Sørhaug²,

Grønberg³

et al. 2020

Tidsskriftet

Self Cite

View full text Add to dashboard Cite

Odd Terje Brustugun er dr.med., spesialist i onkologi og overlege ved Onkologisk seksjon, Vestre Viken, Drammen sykehus. Han er leder i Norsk lungekreftgruppe. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. SVEINUNG SØRHAUG Sveinung Sørhaug er ph.d., spesialist i lungesykdommer, overlege ved Lungemedisinsk avdeling, St. Olavs hospital, og førsteamanuensis ved Institutt for sirkulasjon og bildediagnostikk, NTNU. Han er nestleder i Norsk lungekreftgruppe. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. BJØRN HENNING GRØNBERG Bjørn Henning Grønberg er ph.d., spesialist i onkologi, overlege ved Kreftavdelingen, St. Olavs hospital, og professor ved Institutt for klinisk og molekylaer medisin, NTNU. Han er styremedlem i Norsk lungekreftgruppe. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. MARIANNE AANERUD Marianne Aanerud er ph.d., spesialist i lungesykdommer, overlege ved Lungeavdelinga, Haukeland universitetssjukehus, og førsteamanuensis ved Klinisk institutt 2, Universitetet i Bergen. Hun er styremedlem i Norsk lungekreftgruppe. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. MOHAMMED MODAR ZAYD AL-ZUBAYIDY Mohammed Modar Zayd Al-Zubayidy er spesialist i onkologi og overlege ved Avdeling for kreftbehandling og medisinsk fysikk, Haukeland universitetssjukehus. Han er styremedlem i Norsk lungekreftgruppe. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. LARS FJELLBIRKELAND Lars Fjellbirkeland er dr.med., spesialist i lungesykdommer, overlege ved Lungeavdelingen, Oslo universitetssykehus, Rikshospitalet, og førsteamanuensis ved Institutt for klinisk medisin, Universitetet i Oslo. Han er styremedlem i Norsk lungekreftgruppe. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. ÅSLAUG HELLAND Åslaug Helland er dr.med., spesialist i onkologi, overlege ved Avdeling for kreftbehandling, Oslo universitetssykehus, og professor ved Institutt for klinisk medisin, Universitetet i Oslo. Hun er styremedlem i Norsk lungekreftgruppe. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. Lungekreft: Forbedret prognose gir kapasitetsutfordringer | Tidsskrift for Den norske legeforening JANNA BERG Janna Berg er spesialist i lungesykdommer og overlege ved Lungemedisinsk seksjon, Sykehuset i Vestfold. Hun er styremedlem i Norsk lungekreftgruppe. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. BRYNJAR ANDREASSEN Brynjar Andreassen er spesialist i lungesykdommer og overlege ved Medisinsk avdeling, Helgelandssykehuset, Mo i Rana. Han er styremedlem i Norsk lungekreftgruppe. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter.

show abstract

A 10‐year prediagnostic follow‐up study shows that serum RNA signals are highly dynamic in lung carcinogenesis

et al. 2020

Self Cite

View full text Add to dashboard Cite

The majority of lung cancer (LC) patients are diagnosed at a late stage, and survival is poor. Circulating RNA molecules are known to have a role in cancer; however, their involvement before diagnosis remains an open question. In this study, we investigated circulating RNA dynamics in prediagnostic LC samples, focusing on smokers, to identify if and when diseaserelated signals can be detected in serum. We sequenced small RNAs in 542 serum LC samples donated up to 10 years before diagnosis and 519 matched cancer-free controls coming from 905 individuals in the Janus Serum Bank. This sample size provided sufficient statistical power to independently analyze time to diagnosis, stage, and histology. The results showed dynamic changes in differentially expressed circulating RNAs specific to LC histology and stage. The greatest number of differentially expressed RNAs was identified around 7 years before diagnosis for earlystage LC and 1-4 years prior to diagnosis for locally advanced and advanced-stage LC, regardless of LC histology. Furthermore, NSCLC and SCLC histologies have distinct prediagnostic signals. The majority of differentially expressed RNAs were associated with cancer-related pathways. The dynamic RNA signals pinpointed different phases of tumor development over time. Stage-specific RNA profiles may be associated with tumor aggressiveness. Our results improve the molecular understanding of carcinogenesis. They indicate substantial opportunity for screening and improved treatment and will guide further research on early detection of LC. However, the dynamic nature of the RNA signals also suggests challenges for prediagnostic biomarker discovery.

show abstract

Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016

Cited by 34 publications

References 32 publications

Patterns of survival and surgical treatment in lung cancer patients in Estonia by histologic type and stage, 1996–2016

Patterns of survival and surgical treatment in lung cancer patients in Estonia by histologic type and stage, 1996–2016

Lungekreft: Forbedret prognose gir kapasitetsutfordringer

A 10‐year prediagnostic follow‐up study shows that serum RNA signals are highly dynamic in lung carcinogenesis

Contact Info

Product

Resources

About